The financial impact of heparin-induced thrombocytopenia

Chest

Volumn 134, Issue 3, 2008, Pages 568-573

  Smythe, Maureen A ^a,b   Koerber, John M ^a   Fitzgerald, Maureen ^a   Mattson, Joan C ^a  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

Author keywords

Heparin; Heparin induced thrombocytopenia; Thrombocytopenia; Thrombosis

Indexed keywords

HEPARIN;

AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; FEMALE; FINANCIAL MANAGEMENT; HUMAN; LENGTH OF STAY; MALE; MEDICARE; MORTALITY; PRIORITY JOURNAL; THROMBOCYTOPENIA;

EID: 51649129542     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.08-0120     Document Type: Article

References (19)

1. Davoren A, Aster AH. Heparin induced thrombocytopenia and thrombosis. Am J Hematol 2006; 81:36-44
2. Warkentin TE, Greinacher A. Heparin induced thrombocytopenia: recognition, treatment and prevention; the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126(suppl):311s-337s
3. Prandoni P, Siragusa S, Girolami B, et al. The incidence of heparin induced thrombocytopenia in medical patients treated with low molecular weight heparin: a prospective cohort study. Blood 2005; 106:3049-3054
4. Warkentin TE, Sheppard JA, Sigouin CS, et al. Gender imbalance and risk factor interactions in heparin induced thrombocytopenia. Blood 2006; 108:2937-2941
5. Warkentin TE. New approaches to the diagnosis of heparin induced thrombocytopenia. Chest 2005; 127(suppl):35S-45S
6. Greinacher A, Warkentin TE. Recognition, treatment and prevention of heparin-induced thrombocytopenia: review and update. Thromb Res 2006; 118:165-176
7. Greinacher A, Farner B, Kroll H, et al. Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis, a retrospective analysis of 408 patients. Thromb Res 2005; 94:132-135
8. Lubenow N, Eichler P, Lietz T. Lepirudin in patients with heparin induced thrombocytopenia: results of the third prospective study (HAT-3) and a combined analysis of HAT-1, HAT-2 and HAT-3. J Thromb Haemost 2005; 3:2428-2436
9. Lewis BE, Wallis DE, Berkowitz SD, et al. Argatroban anticoagulant therapy in patients with heparin induced thrombocytopenia. Circulation 2001; 103:1838-1843
10. Lewis BE, Wallis DE, Leya F, et al. Argatroban anticoagulation in patients with heparin induced thrombocytopenia. Arch Intern Med 2003; 163:1849-1856
11. Smythe MA, Koerber JM, Mattson JC. The incidence of recognized heparin induced thrombocytopenia in a large, tertiary care teaching hospital. Chest 2007; 131:1644-1649
12. Arepally GM, Ortel TL. Heparin induced thrombocytopenia. N Engl J Med 2006; 355:809-817
13. Greinacher A, Eichler P, Lietz T, et al. Replacement of unfractionated heparin by low molecular weight heparin for postorthopedic surgery antithrombotic prophylaxis lowers the overall risk of symptomatic thrombosis because of a lower frequency of heparin induced thrombocytopenia. Blood 2005; 106:2921-2922
14. Locke CFS, Dooley J, Gerber J. Rates of clinically apparent heparin-induced thrombocytopenia for unfractionated heparin vs. low molecular weight heparin in non-surgical patients are low and similar. Thromb J 2005; 3:4
15. Warkentin TE, Greinacher A. So, does low-molecular weight heparin cause less heparin-induced thrombocytopenia than unfractionated heparin or not? Chest 2007; 132:1108-1110
16. Warkentin TE, Maurer BT, Aster RH. Heparin induced thrombocytopenia associated with fondaparinux. N Engl J Med 2007; 21:2653-2655
17. McGarry LJ, Thompson D, Weinstein MC, et al. Cost effectiveness of thromboprophylaxis with a low molecular weight heparin versus unfractionated heparin in acutely ill medical patients. Am J Manag Care 2004; 10:632-642
18. Creekmore FM, Oderda GM, Pendleton RC, et al. Incidence and economic implications of heparin induced thrombocytopenia in medical patients receiving prophylaxis for venous thromboembolism. Pharmacotherapy 2006; 26:1438-1445
19. Frame JN. The heparin induced thrombocytopenia task force model: implementing quality improvement and economic outcome initiatives. Semin Hematol 2005; 42(suppl):28S-35S